Abstract
Multiple myeloma (MM) is a clonal neoplasm characterized by expansion of malignant plasma cells in the bone marrow causing various complications including osteolytic lesions and impaired immune function. It has recently been reported that human myeloma cells express multiple Toll-like receptors (TLRs), and their activation-induced functional responses show heterogeneity among cell lines and patient samples. TLRs are critical germ-line encoded molecules expressed in immune cells as well as in a variety of cancer cells. In multiple myeloma, they may induce cell growth and proliferation or promote cell death. In fact, our current knowledge of Toll-like receptor function has gone beyond their main function as triggers of innate and adaptive immune responses. Considering the essential role of bone marrow microenvironment components in myeloma tumor expansion, survival, invasion and drug resistance, TLR triggering may contribute to adhesion-induced or de novo drug resistance of MM cells. Future preclinical and clinical studies are needed to address if TLRs can be exploited as novel therapeutic targets for MM.
Keywords: Bone marrow, drug resistance, inflammation, multiple myeloma, toll like receptors.
Current Molecular Medicine
Title:Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis
Volume: 14 Issue: 4
Author(s): J. Abdi, J. Garssen and F. Redegeld
Affiliation:
Keywords: Bone marrow, drug resistance, inflammation, multiple myeloma, toll like receptors.
Abstract: Multiple myeloma (MM) is a clonal neoplasm characterized by expansion of malignant plasma cells in the bone marrow causing various complications including osteolytic lesions and impaired immune function. It has recently been reported that human myeloma cells express multiple Toll-like receptors (TLRs), and their activation-induced functional responses show heterogeneity among cell lines and patient samples. TLRs are critical germ-line encoded molecules expressed in immune cells as well as in a variety of cancer cells. In multiple myeloma, they may induce cell growth and proliferation or promote cell death. In fact, our current knowledge of Toll-like receptor function has gone beyond their main function as triggers of innate and adaptive immune responses. Considering the essential role of bone marrow microenvironment components in myeloma tumor expansion, survival, invasion and drug resistance, TLR triggering may contribute to adhesion-induced or de novo drug resistance of MM cells. Future preclinical and clinical studies are needed to address if TLRs can be exploited as novel therapeutic targets for MM.
Export Options
About this article
Cite this article as:
Abdi J., Garssen J. and Redegeld F., Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis, Current Molecular Medicine 2014; 14 (4) . https://dx.doi.org/10.2174/1566524014666140414204100
DOI https://dx.doi.org/10.2174/1566524014666140414204100 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis, DNA Binding Ability and Anticancer Activity of 2-heteroaryl Substituted Benzimidazoles Linked Pyrrolo[2,1-c][1,4]benzodiazepine Conjugates
Medicinal Chemistry Quantitative Structure-Activity Relationship Studies: Understanding the Mechanism of Tyrosine Kinase Inhibition
Current Enzyme Inhibition The Role of Tumor Suppressor DLC-1: Far From Clear
Anti-Cancer Agents in Medicinal Chemistry Targeting Cyclooxygenase-2 in Hematological Malignancies: Rationale and Promise
Current Pharmaceutical Design New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension
Current Medicinal Chemistry To Be, or Not To Be: That is the Question-Lineage Commitment in Hematopoiesis
Current Immunology Reviews (Discontinued) Cell Responses to Oxidative Stressors
Current Pharmaceutical Design AIDS Related Viruses, their Association with Leukemia, and Raf Signaling
Current HIV Research AG490 Promotes HIF-1α Accumulation by Inhibiting Its Hydroxylation
Current Medicinal Chemistry Rho-Signaling Pathways in Chronic Myelogenous Leukemia
Cardiovascular & Hematological Disorders-Drug Targets The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism Can the Use of HIV-1 Derived Gene Transfer Vectors for Clinical Application be Justified?
Current Gene Therapy Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)
Current Cancer Drug Targets Foamy Virus Vectors: An Awaited Alternative to Gammaretro- and Lentiviral Vectors
Current Gene Therapy Dynamics of CD86 Expression on Allergic Inflammation - New Insights
Recent Patents on Inflammation & Allergy Drug Discovery Microglia Phenotype Diversity
CNS & Neurological Disorders - Drug Targets Rhein Derivatives, A Promising Pivot?
Mini-Reviews in Medicinal Chemistry Progresses in TCM Metal-Based Antitumour Agents
Anti-Cancer Agents in Medicinal Chemistry The Role of CXC-Chemokine IL-8, IL-6 and CXCR2 Receptor in Lymphoplasmacytic Lymphoma: Correlations with Microvascular Characteristics and Clinical Features
Current Angiogenesis (Discontinued) MicroRNAs - Key Players in Haematopoiesis
Current Signal Transduction Therapy